160 related articles for article (PubMed ID: 21646613)
1. Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.
Maldonado NI; Cabanillas F; Jaffe ES; Raffeld M; Lozada L
J Clin Oncol; 2011 Aug; 29(22):e658-60. PubMed ID: 21646613
[No Abstract] [Full Text] [Related]
2. [Post-transplantation lymphoproliferative disorder in childhood].
Stréhn A; Szőnyi L; Kriván G; Kovács L; Reusz G; Szabó A; Rényi I; Kovács G; Dezsőfi A
Orv Hetil; 2014 Feb; 155(8):313-8. PubMed ID: 24534879
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder of plasma cell type following allogeneic haemopoietic stem cell transplant treated with rituximab.
Getta B; Kwan J
Intern Med J; 2014 Aug; 44(8):821. PubMed ID: 25081050
[No Abstract] [Full Text] [Related]
4. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.
O'Dwyer ME; Launder T; Rabkin JM; Nichols CR
Leuk Lymphoma; 2000 Oct; 39(3-4):411-9. PubMed ID: 11342323
[TBL] [Abstract][Full Text] [Related]
6. Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantation.
Tanaka T; Takizawa J; Miyakoshi S; Kozakai T; Fuse K; Shibasaki Y; Moriyama M; Ohshima K; Toba K; Furukawa T; Sone H; Masuko M
Intern Med; 2014; 53(18):2115-9. PubMed ID: 25224199
[TBL] [Abstract][Full Text] [Related]
7. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
8. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI
Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
[TBL] [Abstract][Full Text] [Related]
9. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
11. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab.
Entz-Werle N; Cojean N; Barats A; Eyer D; Munzer M; Uring-Lambert B; Falkenrodt A; Babin A; Lutz P
Pediatr Transplant; 2003 Aug; 7(4):277-81. PubMed ID: 12890005
[TBL] [Abstract][Full Text] [Related]
14. Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab.
Courby S; Fabre B; Salameire D; Gaulard P; Hincky-Vitrat V; Gressin R; Bonaz B; Epaulard O
Leuk Lymphoma; 2010 Jan; 51(1):174-7. PubMed ID: 20001240
[No Abstract] [Full Text] [Related]
15. EBV-induced post-transplant lymphoproliferative disorder (PTLD).
Birkeland SA; Hamilton-Dutoit S; Sandvej K; Andersen HM; Bendtzen K; Møller B; Jørgensen KA
Transplant Proc; 1995 Dec; 27(6):3467-72. PubMed ID: 8540055
[No Abstract] [Full Text] [Related]
16. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis.
Satou A; Kohno A; Fukuyama R; Elsayed AA; Nakamura S
Hum Pathol; 2017 Jan; 59():147-151. PubMed ID: 27569297
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after a cord blood stem cell transplantation presenting with pulmonary nodules.
Shimasaki N; Mori T; Shimada H; Sugita M; Higuchi M; Mukai M; Morio T; Okamoto S
J Pediatr Hematol Oncol; 2004 Feb; 26(2):124-7. PubMed ID: 14767205
[TBL] [Abstract][Full Text] [Related]
19. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab.
Ifthikharuddin JJ; Mieles LA; Rosenblatt JD; Ryan CK; Sahasrabudhe DM
Am J Hematol; 2000 Oct; 65(2):171-3. PubMed ID: 10996837
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders.
Faye A; Van Den Abeele T; Peuchmaur M; Mathieu-Boue A; Vilmer E
Lancet; 1998 Oct; 352(9136):1285. PubMed ID: 9788467
[No Abstract] [Full Text] [Related]
[Next] [New Search]
